Fundraising FoxFannin Goldenrod Holdings — Full Portfolio
3 tracked investments · listed companies and verified rows first
Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.
BiotechDeep TechHealthtechMedical DevicesHouston, US
Corey Hopkins(Chair of the Department of Pharmaceutical Sciences and Director of the Center for Drug Design and Innovation at UNMC)Dev Chatterjee(Executive Officer)inLeo Linbeck IV(Executive Officer)Mark Worscheh(Executive Officer, Director)in
BoardAtul Varadhachary(Executive Officer, Director)
Board seatLeo Linbeck III· per SEC Form D · $6.5M raise · filed Jun 2026
Procyrion develops medical devices for circulatory support in heart failure treatment, supported by a team of cardiologists and medical device industry veterans.
BiotechHealthtechMedical DevicesHouston, US
Reynolds, III M. Delagado(Director)Benjamin A. Hertzog(Executive Officer, Director)Dr. Fain(Founder/Executive)Jason J Heuring(Executive Officer)Bryan E. Nearn(Vice President)
BoardLeo III E Linbeck(Director)
Board seatLeo E Linbeck, III· per SEC Form D · $64M raise · filed Feb 2024
Co-investorsBluebird VenturesScientific Health DevelopmentTexas Ventures
Pulmotect develops immunomodulatory inhaled therapies designed to activate the lungs' innate immune system for preventing and treating respiratory complications in immunosuppressed patients and other high-risk populations.
BiotechHealthtechMedical DevicesHouston, US
Colin Broom(Executive Officer, Director)in
BoardKumar Srinivasan(Director)Atul Varadhachary(Director)Brenton Scott(President and Chief Operating Officer, Co-founder)Mark Worscheh(Director)in
Board seatLeo E. LinbeckLeo E. Linbeck IIILeo Linbeck III· per SEC Form D · filed Sep 2024
Co-investorsTexas Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.